# SCNX catalysts: Scienture Holdings, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/scnx/catalysts

> Scienture Holdings, Inc. (SCNX) has no upcoming catalysts in this calendar. The latest recorded is the Scienture Holdings, Inc. earnings report, August 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SCNX?

Scienture Holdings, Inc. (SCNX) has no upcoming catalysts in this calendar. The latest recorded is the Scienture Holdings, Inc. earnings report, August 14, 2026. Press release filed with the SEC (EX-99): "NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026." [Calendar and source filings](https://sec-api.dev/companies/scnx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001493152-26-039474, https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-08-20. Cite: https://sec-api.dev/companies/scnx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Scienture Holdings, Inc. |
| Ticker | SCNX (Nasdaq) |
| SEC CIK | 1382574 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/scnx |

## Cash runway

Cash $8.2M as of 2026-06-30; quarterly burn $3.1M; about 7.8 months of runway at that rate (XBRL company facts, accession 0001493152-26-037754).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 19, 2024 | [REZENOPY (SCN-110) FDA approval](https://sec-api.dev/pdufa/scn-110) | SCNX |  | completed, approved | "LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/ex99-1.htm)) |
| April 19, 2024 | [Rezenopy (naloxone hydrochloride) FDA approval](https://sec-api.dev/pdufa/naloxone) | SCNX |  | completed, approved | "NDA215487 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20240419, review_priority STANDARD; sponsor_name SCIENTURE; product REZENOPY (NALOXONE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215487%22)) |
| August 19, 2024 | [ARBLI (losartan) complete response letter (CRL)](https://sec-api.dev/pdufa/losartan) | SCNX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22218772_2025_Orig1s000OtherActionLtrs.pdf%22)) |
| 2025 | [SCN-107 trial start](https://sec-api.dev/pdufa/scn-107) | SCNX |  | scheduled | "Scienture anticipates submitting an IND and, if cleared by the FDA, initiating a Phase 1 single dose study in healthy adults in 2025 to conduct an initial assessment of safety and tolerability of SCN-107." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1382574/000149315225022032/form10-q.htm)) |
| March 13, 2025 | [ARBLI (losartan) FDA approval](https://sec-api.dev/pdufa/losartan) | SCNX |  | completed, approved | "NDA218772 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250313, review_priority STANDARD; sponsor_name SCIENTURE; product ARBLI (LOSARTAN POTASSIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218772%22)) |
| March 17, 2025 | [Scienture Holdings, Inc. PDUFA date](https://sec-api.dev/companies/scnx/catalysts) | SCNX |  | scheduled | "In October 2024, the FDA accepted the resubmitted NDA for review and assigned a PDUFA target action date of March 17, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1382574/000149315226013475/form10-k.htm)) |
| May 18, 2026 | [Scienture Holdings, Inc. earnings report](https://sec-api.dev/companies/scnx/catalysts) | SCNX |  | completed | "Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/ex99-1.htm)) |
| August 14, 2026 | [Scienture Holdings, Inc. earnings report](https://sec-api.dev/companies/scnx/catalysts) | SCNX |  | completed | "NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/ex99-1.htm)) |

## Drugs

- [ARBLI (losartan)](https://sec-api.dev/pdufa/losartan): 
- [Rezenopy (naloxone hydrochloride)](https://sec-api.dev/pdufa/naloxone): 
- [SCN-107](https://sec-api.dev/pdufa/scn-107): 
- [REZENOPY (SCN-110)](https://sec-api.dev/pdufa/scn-110): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/scnx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SCNX catalysts: Scienture Holdings, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/scnx/catalysts

```bibtex
@misc{secapidev_companies_scnx_catalysts_20261116,
  title        = {SCNX catalysts: Scienture Holdings, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/scnx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_scnx_catalysts_20261116","title":"SCNX catalysts: Scienture Holdings, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/scnx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
